Shabnam Shalapour
Cancer is characterized by accumulation and loss of normal cellular regulatory processes, leading to expression of tumor-specific molecules (antigens). The tumor microenvironment also causes exhaustion of the patient’s immune response...Read More
Michael Schweizer, MD
Dr. Michael Schweizer is an Assistant Professor at the Department of Medicine at the Division of Medical Oncology at the University of Washington School of Medicine. He also is a...Read More
Saul Priceman
Supplementing a patient’s immune response by engineering their killer white blood cells (CAR T-cells) to recognize, bind to, and eliminate the tumor is a new and transformational area of cancer...Read More
Sean McGuire
New hormonal treatments for prostate cancer such as Xtandi® and Zytiga® are effective, but patients invariably become resistant to these medications. Dr. Sean McGuire’s innovative research is evaluating potential therapeutic...Read More
Ravi Madan
Immune checkpoint inhibitors “take the brakes” off a patient immune response, resulting in immune elimination of the cancer. Patients with melanoma, renal, bladder, lymphoma and lung cancers have been successfully...Read More
Zhenfei Li
While most men with prostate cancer initially respond well to androgen deprivation therapies (ADT) such as Zytiga®, some do not, and patients inevitably develop resistance to treatment. Recent research has...Read More
John Kyung Lee
A highly aggressive subtype of treatment-resistant prostate cancer has been increasingly diagnosed in men who have suffered from the disease and were treated with androgen deprivation therapy. Small cell neuroendocrine...Read More
Vishal Kothari
New therapeutic targets and prognostic biomarkers for treatment-resistance prostate cancer (CRPC) would greatly improve outlook and decrease mortality rates for men with advanced forms of this disease. Recent research has...Read More
Joseph Ippolito
Metabolic oxidative phosphorylation (OXPHOS) is a biochemical process that may lead to therapy resistance and tumor recurrence in men with prostate cancer. Characterizing the metabolism of treatment-resistant prostate cancer (CRPC)...Read More